Zentek's half-year profit comes from accounting gain, not sales, as C$18M raise lifts cash
A C$19.7M non-cash write-back turned Zentek's six months to September into a C$15.2M profit, while revenue stayed negligible and spending climbed.
17 Nov 2026 · Zentek Ltd. ZTEKF · Company news
Zentek Ltd. has swung to a C$15.2M net profit for the six months ended 30 September 2026, but the figure owes nothing to commercial traction. The Canadian company's board approved its unaudited interim statements on 16 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Zentek Ltd. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More EarningsAll →
Earnings
Prenetics widens H2 EBITDA loss guidance to $30-35M as IM8 spending rises
18 Nov 2026 · Prenetics Global Ltd PRE · Company news
Earnings
newcleo reports Q3 revenue of about €10M and €233.4M cash as PRECURSOR e-core completed
18 Nov 2026 · newcleo plc NWCL · Company news
Earnings
Iridex cuts 2026 revenue guidance to $46-48M after 19% third-quarter sales drop
17 Nov 2026 · Iridex Corp IRIX · Company news
Earnings
Interpace Biosciences Q3 revenue rises 18% to $10.4M on thyroid testing growth
17 Nov 2026 · Interpace Biosciences, Inc. IDXG · Company news
Earnings
Vivos Therapeutics regains Nasdaq equity compliance as Q3 revenue rises 24% sequentially
17 Nov 2026 · Vivos Therapeutics, Inc. VVOS · Company news
Earnings
Mesoblast reports US$115M first full-year Ryoncil sales and advances four late-stage programmes
17 Nov 2026 · Mesoblast Ltd MESO · Company news